Gaithersburg, Maryland – December 19, 2018: MaxCyte announced today that Debra K. Bowes , Chief Business Officer, CARMA™ Cell Therapy, and Claudio Dansky Ullmann , MD, Chief Medical Officer, will present on the company’s CARMA platform at two upcoming industry conferences: the Biotech Showcase
Gaithersburg, Maryland – October 30, 2018: MaxCyte announced today that Debra K. Bowes , Chief Business Officer, CARMA Cell Therapy, will present “Novel mRNA-based Autologous CAR Therapies in Oncology” at the 24th Annual International Partnering Conference BIO-EUROPE.
Gaithersburg, Maryland – August 29, 2018 – MaxCyte announced today that Debra K. Bowes, Chief Business Officer, CARMA Cell Therapy, will present “Novel mRNA-based Autologous CAR Therapies in Oncology” at two upcoming industry conferences. On September 5, 2018, at 2:45 p.m.
Gaithersburg, Maryland – January 2, 2018 : MaxCyte announced today that Debra K. Bowes, Executive Vice President, Business and Strategic Development , will present at two life sciences conferences this month: the Biotech Showcase on January 8 at 3:30 p.m.
Gaithersburg, Maryland – September 14, 2017 : MaxCyte, a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, announced today that Madhusudan V. Peshwa, PhD, MaxCyte Chief Scientific Officer,
25-year biopharma industry veteran joins the Company to drive further growth of its innovative high-performance cell engineering platform for use in commercial drug development Gaithersburg, Maryland – August 14, 2017: MaxCyte, a US-based global company dedicated to driving the acceleration of the
Gaithersburg, MD, January 16, 2017 – MaxCyte®, Inc., developer and supplier of cell engineering products and technologies to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, announced today that Madhusudan V.
Preclinical research to focus on developing therapies based on MaxCyte’s proprietary CARMA platform – CARMA has potential for broad applicability against solid or liquid tumor indications Gaithersburg, MD, December 21, 2016 – MaxCyte®, Inc. today announces a strategic collaboration with
Biotech industry veteran to lead alliance-building efforts for MaxCyte’s proprietary CARMA platform Gaithersburg, Maryland – November 2, 2016 – MaxCyte, Inc., a developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and
Gaithersburg, MD, 29 September 2016 – MaxCyte®, Inc., an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and
